403
Sorry!!
Error! We're sorry, but the page you were looking for doesn't exist.
Middle East AI In Oncology Market Size To Hit USD 812.89 Million By 2034
| Incidence | Mortality |
| Country | In 2020 | In 2040 | % Increase | In 2020 | In 2040 | % Increase |
| Bahrain | 1205 | 3239 | 168.8 | 592 | 1890 | 219.3 |
| Kuwait | 3824 | 10,684 | 179.4 | 1718 | 5963 | 247.1 |
| Oman | 3664 | 8360 | 128.2 | 2019 | 5281 | 161.6 |
| Qatar | 1472 | 5498 | 273.5 | 703 | 3249 | 362.2 |
| Saudi Arabia | 27,578 | 59,694 | 116.5 | 12,986 | 32,728 | 152 |
| UAE | 4732 | 15,667 | 231.1 | 1877 | 8154 | 334.4 |
| All GCC countries | 42,475 | 103,142 | 142.8 | 19,895 | 57,265 | 187.8 |
What are the Primary Growth Drivers of the Middle East AI in Oncology Market?
The key growth drivers of the market include the rising incidence of cancer, increasing adoption of advanced AI technologies for early detection and precision treatment, and growing government support for digital healthcare transformation. Additionally, expanding collaborations between technology providers and healthcare institutions, along with rising awareness of AI's role in improving cancer care outcomes, are fueling market growth across the region.
Why should you buy this report?
- Comprehensive Market Analysis: Gain detailed insights into the industry across major regions and segments. Competitive Landscape: Explore the market presence of key players. Future Trends: Discover pivotal trends and drivers shaping the future of the market. Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
Middle East AI In Oncology Market Report Scope
| Report Attribute | Details |
| Market size value in 2025 | USD 136.17 Million |
| Revenue forecast in 2034 | USD 812.89 Million |
| Growth rate | CAGR of 21.96% from 2025 to 2034 |
| Actual data | 2021 - 2024 |
| Forecast period | 2025 - 2034 |
| Quantitative units | Revenue in USD million, and CAGR from 2025 to 2034 |
| Report coverage | Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
| Segments covered | Component, Cancer Type, Application, End-use |
| Regional scope | Middle East |
| Country scope | Saudi Arabia; UAE; Qatar; Oman; Kuwait |
| Key companies profiled | Lunit Inc.; Siemens Healthineers AG; GE HealthCare; NVIDIA Corporation; Roche; Insilico Medicine; Oracle; Intel Corporation |
| Customization scope | Free report customization (equivalent up to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope. |
For more information, visit the Nova One Advisor website or email the team at ... | Call us: +1 804 420 9370
What are the Key trends in the Middle East AI in Oncology Market in 2024?
- In August 2023, MBZUAI developed an AI model capable of accurately generating and identifying different cancer tissue images using few-shot learning techniques. In May 2023, Cleveland Clinic Abu Dhabi launched the Fatima bint Mubarak Center, featuring Ethos adaptive radiotherapy technology that uses AI and machine learning to enhance cancer treatment precision.
What is the Appearing Challenge in the Middle East AI in Oncology Market?
The major challenges in the market include limited availability of skilled professionals, high implementation costs, and a lack of standardized data for AI model training. Additionally, concerns over data privacy, inadequate digital infrastructure in some regions, and slow adoption of advanced technologies across smaller healthcare facilities hinder widespread AI integration in oncology across the Middle East.
Segmental Insights
By Technology Insights
What made the Hardware Segment Dominant in the Middle East AI in Oncology Market in 2024?
In 2024, the hardware segment led the market due to rising investments in advanced computing infrastructure, including GPUs and AI-enabled medical imaging systems. The growing need for high-performance hardware to support complex AI algorithms and real-time cancer diagnosis drove demand. Additionally, hospitals and research centers increasingly adopted modern diagnostic devices to enhance accuracy and processing speed in oncology applications.
The software segment is expected to grow at the fastest CAGR in the market in 2024 due to the increasing adoption of AI-driven diagnostic tools, cloud-based analytics, and precision treatment solutions. Continuous advancements in machine learning algorithms, integration with electronic health records, and the need for scalable, cost-efficient systems are driving software demand. Moreover, software offers flexibility and easy updates, supporting rapid technological innovation in oncology care.
By Cancer Type Insights
How did Health and Wellness-predisposition/Risk/Tendency Segment Dominate the Middle East AI in Oncology Market in 2024?
In 2024, the breast cancer
The prostate cancer
By Application Insights
Why the Diagnostics Segment Dominated the Middle East AI in Oncology Market in 2024?
In 2024, the diagnostics segment held the highest market share in the market due to the widespread adoption of AI-based imaging and screening tools for early cancer detection. The growing need for accurate, fast, and non-invasive diagnostic solutions drove demand. Additionally, hospitals and diagnostic centers increasingly leverage AI algorithms to improve detection accuracy, reduce diagnostic errors, and enhance clinical decision-making in oncology care.
The research and development segment is expected to grow at the fastest CAGR during the forecast period due to increasing investments in AI-driven cancer research and drug discovery. Advancements in machine learning and data analytics are enabling faster identification of biomarkers and treatment targets. Additionally, growing collaborations between research institutes, biotech firms, and healthcare providers are accelerating innovation in oncology, boosting the adoption of AI for R&D applications across the region.
By End User Insights
What Made the Hospitals Segment Dominant in the Middle East AI in Oncology Market in 2024?
In 2024, the hospital segment dominated the market due to the widespread integration of AI-based diagnostic and treatment systems in hospital settings. Hospitals increasingly adopted advanced imaging tools and predictive analytics to enhance cancer detection accuracy and patient outcomes. Additionally, strong government funding, improved healthcare infrastructure, and the presence of specialized oncology departments supported hospitals' leading role in implementing AI technologies.
The surgical centers and medical institutes segment is expected to grow at a faster CAGR during the forecast period due to the rising adoption of AI-assisted surgical systems and precision oncology tools. Increasing focus on research collaborations, clinical trialsBy Regional Analysis
How is Saudi Arabia contributing to the Expansion of the Middle East AI in Oncology Market?
Saudi Arabia dominated the market due to its strong healthcare infrastructure, significant government investments in AI and digital health, and rising cancer prevalence. The country's Vision 2030 initiative has accelerated the adoption of advanced technologies in healthcare, including AI-based diagnostics and treatment solutions. Additionally, partnerships between international tech companies and Saudi healthcare institutions have enhanced cancer detection and management capabilities, strengthening the nation's leadership in AI-driven oncology.
How is Asia-Pacific Accelerating the Middle East AI in Oncology Market?
The UAE is expected to grow at the fastest CAGR in the market due to its rapid digital transformation, strong government support for AI adoption, and expanding healthcare investments. The country's focus on smart healthcare initiatives, such as AI-based diagnostics and precision medicine, is driving growth. Additionally, collaborations with global technology companies and the establishment of advanced cancer care centers are boosting the integration of AI solutions in oncology across the UAE.
Middle East AI in Oncology Market - Value Chain Analysis
1. Data Collection and Annotation
This stage involves gathering vast amounts of oncology-related data, such as medical imaging2. AI Algorithm Development
At this stage, developers design and train AI models using machine learning and deep learning techniques tailored for oncology applications like tumor detection, treatment planning, and prognosis prediction. Innovation and accuracy are the focus here.
3. Platform and Software Development
AI solutions are packaged into user-friendly platforms and software that can be integrated into clinical workflows. These platforms offer diagnostic support, treatment recommendations, and data analytics for healthcare professionals.
4. Implementation and Integration
Hospitals and healthcare providers implement AI systems into their oncology departments, ensuring compatibility with existing electronic health records (EHR) and imaging equipment. Training healthcare staff to effectively use AI tools is also vital.
5. Maintenance and Support
Ongoing maintenance, software updates, and technical support are essential to keep AI systems accurate and secure. This stage also involves monitoring AI performance and ensuring compliance with data privacy regulations.
6. Research and Development (R&D)
Continuous R&D helps improve AI capabilities and discover new applications in oncology, such as personalized medicine and early cancer detection. Partnerships between AI firms, healthcare institutions, and academic bodies drive innovation.
Key Players Operating in the Market
1. Lunit Inc.: Lunit's AI-powered imaging solutions, such as Lunit INSIGHT MMG, have been integrated into national cancer screening programs in Qatar and the UAE. These tools assist in early breast cancer detection, aiming to reduce missed diagnoses and improve survival rates.
2. Siemens Healthineers AG: It offers advanced imaging systems and AI-driven analytics platforms that enhance diagnostic accuracy in oncology. Their technologies support clinicians in detecting and characterizing tumors, leading to more precise treatment planning.
3. GE HealthCare: GE HealthCare's AI-enabled imaging and monitoring solutions facilitate real-time analysis of medical images, aiding in the early detection of cancers. Their systems are designed to integrate seamlessly into existing healthcare infrastructures in the Middle East.
4. NVIDIA Corporation: NVIDIA provides high-performance computing platforms essential for training and deploying AI models in oncology. Their GPUs and software frameworks accelerate the development of AI applications for cancer research and treatment.
5. Roche: The company collaborates with AI firms to integrate machine learning into drug discovery and diagnostics. Their efforts focus on personalizing cancer treatments and improving patient outcomes through data-driven insights.
6. Insilico Medicine: Insilico Medicine utilizes AI to design novel small molecules for cancer therapies. Their approach includes the use of generative models to simulate biological data, enhancing the efficiency of drug development processes.
7. Oracle Corporation: Oracle offers cloud-based platforms that support the storage, analysis, and sharing of large-scale oncology datasets. Their solutions enable healthcare providers to implement AI-driven decision-making in cancer care.
8. Intel Corporation: Intel supplies processors and AI accelerators that power computational tasks in oncology research. Their hardware supports the development and deployment of AI applications in cancer diagnostics and treatment planning.
Recent Developments in the Middle East AI in Oncology Market
- In August 2025, Rakovina Therapeutics Inc. partnered with Saudi-based NanoPalm Ltd. to establish a joint venture aimed at developing new oncology drug candidates using AI-driven discovery technologies. In August 2025, Egypt introduced the region's first homegrown AI system for early breast cancer detection at Baheya Hospital, Sheikh Zayed. The system quickly analyzes mammograms, identifies abnormal tissues, classifies them as benign or malignant, and enhances its accuracy through machine learning.
More Insights in Nova One Advisor:
- Oncology Information Systems Market - The global oncology information systems market Radiation Oncology Market - The global radiation oncology market size Interventional Oncology Market - The global interventional oncology market size Hemato Oncology Testing Market - The global hemato oncology testing market size Oncology Companion Diagnostic Market - The global oncology companion diagnostic market Clinical Oncology Next Generation Sequencing Market - The global clinical oncology next generation sequencing market LAMEA Oncology/Anti-Cancer Drugs Market - The global LAMEA oncology/ant-cancer drugs market size Oncology Drugs Market - The global oncology drugs market size U.S. 3D Medical Imaging Devices Market - The U.S. 3D Medical Imaging Devices Market size U.S. Veterinary Oncology Diagnostics Market - The U.S. Veterinary Oncology Diagnostics Market size Blockbuster Oncology Brands Market - The Blockbuster oncology brands market size Oncology Biosimilars Market - The oncology biosimilars market size AI In Oncology Market - The global AI in oncology market size Veterinary Oncology Market - The veterinary oncology market size Immuno-oncology Clinical Trials Market - The global immuno-oncology clinical trials market size
Middle East AI In Oncology Market Report Segmentation
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2019 to 2034. For this study, Nova One Advisor has segmented the Middle East AI in oncology market
By Component
- Software Solutions Hardware Services
By Cancer Type
- Breast Cancer Lung Cancer Prostate Cancer Colorectal Cancer Brain Tumor Other
By Application
- Diagnostics (Pathology, Cancer Radiology) Radiation therapy (Radiotherapy) Research & Development (Drug design, development process, etc.) Chemotherapy Immunotherapy
By End-use
- Hospitals Surgical Centers & Medical Institutes Others (Pharmaceutical companies, Research institutes & training centers)
About-Us
Nova One Advisor is a global leader in market intelligence and strategic consulting, committed to delivering deep, data-driven insights that power innovation and transformation across industries. With a sharp focus on the evolving landscape of life sciences, we specialize in navigating the complexities of cell and gene therapy, drug development, and the oncology market, enabling our clients to lead in some of the most revolutionary and high-impact areas of healthcare.
Our expertise spans the entire biotech and pharmaceutical value chain, empowering startups, global enterprises, investors, and research institutions that are pioneering the next generation of therapies in regenerative medicine, oncology, and precision medicine.
Our Trusted Data Partners
Towards Chemical and Materials | Precedence Research | Statifacts | Towards Packaging | Towards Healthcare | Towards Food and Beverages | Towards Automotive | Towards Consumer Goods | Nova One Advisor | Nutraceuticals Func Foods | Onco Quant | Sustainability Quant | Specialty Chemicals Analytics | Towards Chem and Material Web:Contact Us
USA: +1 804 420 9370
Email: ... For Latest Update Follow Us: LinkedIn
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept
any responsibility or liability for the accuracy, content, images,
videos, licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright
issues related to this article, kindly contact the provider above.
Most popular stories
Market Research
More Story
Comments
No comment